ALX Oncology Initiates Phase 1 Clinical Trial for Promising EGFR-Targeted ADC, ALX2004, in Solid Tumor Treatment
Reuters
Aug 19
ALX Oncology Initiates Phase 1 Clinical Trial for Promising EGFR-Targeted ADC, ALX2004, in Solid Tumor Treatment
ALX Oncology Holdings Inc., a clinical-stage biotechnology company, has announced the initiation of a Phase 1 clinical trial for ALX2004, an epidermal growth factor receptor (EGFR) antibody-drug conjugate $(ADC)$ aimed at treating EGFR-expressing solid tumors. The trial marks the first in-human study of ALX2004 and involves an open-label, multicenter approach. It includes a Phase 1a dose escalation portion focusing on patients with advanced or metastatic non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, and colorectal cancer. The trial will subsequently proceed to a dose exploration and expansion phase. Initial safety data from the study is expected to be available in the first half of 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ALX Oncology Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9514531-en) on August 19, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.